keyword
MENU ▼
Read by QxMD icon Read
search

Price transparency

keyword
https://www.readbyqxmd.com/read/29328844/cost-awareness-of-disposable-surgical-equipment-and-strategies-for-improvement-cross-sectional-survey-and-literature-review
#1
James Wf Kynaston, Thomas Smith, Jeremy Batt
A significant healthcare funding gap has been predicted over the coming years. NHS England has made transparency and cost efficiency a key priority. Healthcare technology accounts for a large portion of healthcare expenditure. The aim of the study was to establish the cost awareness of theatre staff for disposable surgical equipment and to review the current evidence around improving cost awareness. A cross sectional survey was performed. A questionnaire was distributed to consultants, registrars, core surgical trainees and theatre scrub practitioners within an NHS foundation trust and analysed using Microsoft excel 2010...
October 2017: Journal of Perioperative Practice
https://www.readbyqxmd.com/read/29311107/considering-transparency-and-value-for-fairer-drug-prices
#2
Paul Webster
No abstract text is available yet for this article.
January 8, 2018: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/29276253/direct-and-indirect-remuneration-fees-the-controversy-continues
#3
Michael Gabay
The Centers for Medicare and Medicaid Services (CMS) initially created direct and indirect remuneration (DIR) fees with the enactment of Medicare Part D in order to track rebates and other price adjustments made to pharmacy benefit managers (PBMs). PBMs have expanded the use of these fees to "claw back" money from pharmacies on already dispensed medications. Community and specialty pharmacies claim these fees are not transparent, hurt patients and taxpayers, and negatively impact their fiscal bottom line, while PBMs assert that these fees actually reduce premiums for patients...
December 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29261502/-a-pragmatic-approach-to-managing-expensive-therapies
#4
Bertrand Jordan
Inflated drug prices necessarily raise the issue of rational allocation of health care resources. The system operated by the NICE agency in the UK attempts to do this by calculating the cost per quality-adjusted life year gained (QALY) and recommending funding only for drugs whose cost per QALY falls under a certain threshold. The whole process is documented in detail and easily accessible, and often results in significant discounts on drug prices. Given that some kind of rationing of health care is inevitable, the rational and transparent process followed by NICE has a number of positive features...
December 2017: Médecine Sciences: M/S
https://www.readbyqxmd.com/read/29210785/large-variability-in-the-diversity-of-physiologically-complex-surgical-procedures-exists-nationwide-among-all-hospitals-including-among-large-teaching-hospitals
#5
Franklin Dexter, Richard H Epstein, Kokila Thenuwara, David A Lubarsky
BACKGROUND: Multiple previous studies have shown that having a large diversity of procedures has a substantial impact on quality management of hospital surgical suites. At hospitals with substantial diversity, unless sophisticated statistical methods suitable for rare events are used, anesthesiologists working in surgical suites will have inaccurate predictions of surgical blood usage, case durations, cost accounting and price transparency, times remaining in late running cases, and use of intraoperative equipment...
November 22, 2017: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/29200881/do-reimbursement-recommendation-processes-used-by-government-drug-plans-in-canada-adhere-to-good-governance-principles
#6
Nigel Sb Rawson, John Adams
In democratic societies, good governance is the key to assuring the confidence of stakeholders and other citizens in how governments and organizations interact with and relate to them and how decisions are taken. Although defining good governance can be debatable, the United Nations Development Program (UNDP) set of principles is commonly used. The reimbursement recommendation processes of the Canadian Agency for Drugs and Technologies in Health (CADTH), which carries out assessments for all public drug plans outside Quebec, are examined in the light of the UNDP governance principles and compared with the National Institute for Health and Care Excellence system in England...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29180831/internal-conflict-market-uniformity-and-transparency-in-price-competition-between-teams
#7
Michael Kurschilgen, Alexander Morell, Ori Weisel
The way profits are divided within successful teams imposes different degrees of internal conflict. We experimentally examine how the level of internal conflict, and whether such conflict is transparent to other teams, affects teams' ability to compete vis-à-vis each other, and, consequently, market outcomes. Participants took part in a repeated Bertrand duopoly game between three-player teams which had either the same or different level of internal conflict (uniform vs. mixed). Profit division was either private-pay (high conflict; each member received her own asking price) or equal-pay (low conflict; profits were divided equally)...
December 2017: Journal of Economic Behavior & Organization
https://www.readbyqxmd.com/read/29170293/identifying-clinical-features-in-primary-care-electronic-health-record-studies-methods-for-codelist-development
#8
Jessica Watson, Brian D Nicholson, Willie Hamilton, Sarah Price
OBJECTIVE: Analysis of routinely collected electronic health record (EHR) data from primary care is reliant on the creation of codelists to define clinical features of interest. To improve scientific rigour, transparency and replicability, we describe and demonstrate a standardised reproducible methodology for clinical codelist development. DESIGN: We describe a three-stage process for developing clinical codelists. First, the clear definition a priori of the clinical feature of interest using reliable clinical resources...
November 22, 2017: BMJ Open
https://www.readbyqxmd.com/read/29124937/an-implantable-transparent-conductive-film-with-water-resistance-and-ultra-bendability-for-electronic-devices
#9
Youngjun Song, Sejung Kim, Michael J Heller
Recently, instead of indium tin oxide (ITO), the random mesh pattern of metallic nanowires for flexible transparent conducting electrodes (FTCEs) has received a great amount of interest due to its flexibility, low resistance, reasonable price and compliant processes. Mostly, nanowires for FTCEs are fabricated by spray or mayer coating methods. However, the metallic nanowires layer of FTCEs, which is fabricated by these methods, has spiked surface roughness and low junction contact between the nanowires that leads to their high sheet resistance value...
November 10, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29124745/medication-access-in-america-and-medicare-part-d-rx-shopping-saves-but-may-be-costly
#10
Gina Upchurch, Marilyn E Disco, Jessica L Visco, Katie F Huffman
This article is a reflection of some of the changes we have witnessed in pharmacy over the years, including the rise in medication usage and prices and the transformation of how medicines are paid for in the U.S., with growing concern over pricing transparency. We discuss the complex Medicare Part D prescription drug benefit, how enrollees can save by comparing plans annually, and the influence of preferred pharmacies. We review options for medication assistance other than Part D and share our belief that while Medicare Part D has dramatically improved access to medicines, more needs to be done to decrease Medicare's and individuals' out-of-pocket spending, and as importantly, to ensure that medicines are doing more good than harm...
November 9, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29033060/a-review-of-international-coverage-and-pricing-strategies-for-personalized-medicine-and-orphan-drugs
#11
REVIEW
Irina Degtiar
BACKGROUND: Personalized medicine and orphan drugs share many characteristics-both target small patient populations, have uncertainties regarding efficacy and safety at payer submission, and frequently have high prices. Given personalized medicine's rising importance, this review summarizes international coverage and pricing strategies for personalized medicine and orphan drugs as well as their impact on therapy development incentives, payer budgets, and therapy access and utilization...
September 29, 2017: Health Policy
https://www.readbyqxmd.com/read/28955404/responsible-pricing-in-value-based-assessment-of-cancer-drugs-real-world-data-are-an-inevitable-addition-to-select-meaningful-new-cancer-treatments
#12
EDITORIAL
Wim van Harten, Maarten J IJzerman
Recently, NICE was given the task of governing the Cancer Drug Fund (CDF) in the UK as the latter was criticized for allowing too many insufficiently tested drugs to be covered [1, 2]. The CDF was initiated in 2012, but immediately received criticism from several health economists because of the rather strict coverage criteria that are commonly used by NICE for most other health services in the NHS. This led to questions about the use of different reimbursement criteria (why have a different fund otherwise?) for expensive cancer drugs...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28945173/insulin-degludec-versus-insulin-glargine-u100-for-patients-with-type-1-or-type-2-diabetes-in-the-us-a-budget-impact-analysis-with-rebate-tables
#13
Wendy S Lane, James Weatherall, Jens Gundgaard, Richard F Pollock
BACKGROUND AND AIMS: Drug rebates are almost universally negotiated privately between the manufacturer and the payer in the US. The aim of the present study was to illustrate the use of a "rebate table" to improve the transparency and utility of published budget impact analyses in the US by modeling ranges of hypothetical rebates for two comparators. Worked examples were conducted to illustrate the budgetary implications of using insulin degludec (IDeg) relative to insulin glargine (IGlar) U100 in patients with type 1 or 2 diabetes...
October 12, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28944731/the-fda-unapproved-drugs-initiative-an-observational-study-of-the-consequences-for-drug-prices-and-shortages-in-the-united-states
#14
Ravi Gupta, Sanket S Dhruva, Erin R Fox, Joseph S Ross
BACKGROUND: Hundreds of drug products are currently marketed in the United States without approval from the FDA. The 2006 Unapproved Drugs Initiative (UDI) requires manufacturers to remove these drug products from the market or obtain FDA approval by demonstrating evidence of safety and efficacy. Once the FDA acts against an unapproved drug, fewer manufacturers remain in the market, potentially enabling drug price increases and greater susceptibility to drug shortages. There is a need for systematic study of the UDI's effect on prices and shortages of all targeted drugs...
October 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28929871/japanese-healthcare-fostering-competition-and-controlling-costs
#15
James H Tiessen, Ken Kato
Japan's universal healthcare system is relatively inexpensive, provides accessible services, and was established nearly 10 years before Canada's. Two aspects of Japan's system are particularly interesting. The first is that there is active competition for patients between a variety of hospital providers, which can be privately or publicly owned. This competition is based on service quality because prices are set centrally. The second feature is that these prices are adjusted biannually by a National Council, the Chuikyo, that includes payers (employers), providers, and third-party experts in public negotiations...
July 2017: Healthcare Management Forum
https://www.readbyqxmd.com/read/28917469/prior-authorizations-for-dermatologic-medications-an-american-academy-of-dermatology-survey-of-us-dermatology-providers-and-staff
#16
LETTER
Aaron M Secrest, Maryam M Asgari, Arianne S Kourosh, John S Barbieri, Joerg Albrecht
No abstract text is available yet for this article.
October 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28892524/research-and-development-spending-to-bring-a-single-cancer-drug-to-market-and-revenues-after-approval
#17
Vinay Prasad, Sham Mailankody
Importance: A common justification for high cancer drug prices is the sizable research and development (R&D) outlay necessary to bring a drug to the US market. A recent estimate of R&D spending is $2.7 billion (2017 US dollars). However, this analysis lacks transparency and independent replication. Objective: To provide a contemporary estimate of R&D spending to develop cancer drugs. Design, Setting, and Participants: Analysis of US Securities and Exchange Commission filings for drug companies with no drugs on the US market that received approval by the US Food and Drug Administration for a cancer drug from January 1, 2006, through December 31, 2015...
November 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28874405/pediatric-price-transparency-time-to-come-out-of-the-dark
#18
Kirsten Nieto, Christopher Moriates
No abstract text is available yet for this article.
September 5, 2017: Hospital Pediatrics
https://www.readbyqxmd.com/read/28874404/pediatric-price-transparency-still-opaque-with-opportunities-for-improvement
#19
Laura J Faherty, Charlene A Wong, Jordyn Feingold, Joan Li, Robert Town, Evan Fieldston, Rachel M Werner
OBJECTIVES: Price transparency is gaining importance as families' portion of health care costs rise. We describe (1) online price transparency data for pediatric care on children's hospital Web sites and state-based price transparency Web sites, and (2) the consumer experience of obtaining an out-of-pocket estimate from children's hospitals for a common procedure. METHODS: From 2015 to 2016, we audited 45 children's hospital Web sites and 38 state-based price transparency Web sites, describing availability and characteristics of health care prices and personalized cost estimate tools...
September 5, 2017: Hospital Pediatrics
https://www.readbyqxmd.com/read/28859183/association-between-patient-value-systems-and-physician-and-practice-attributes-available-online
#20
Jamie L Welshhans, Jeffrey J Harmon, Ira Papel, Richard Gentile, Devinder Mangat, Patrick Byrne, Ryan M Collar
Importance: The relative value of facial plastic surgeon personal and practice attributes is relevant to the broader health care system because of increasing out-of-pocket expenses to patients. Objective: To determine the relative value of specific facial plastic surgeon personal and practice attributes available online from the perspective of patients. Design, Setting, and Participants: This study consisted of an electronic survey sent to patients by email using choice-based conjoint analysis; surveys were sent between December 2015 and March 2016...
August 31, 2017: JAMA Facial Plastic Surgery
keyword
keyword
80684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"